AA
DRNA

ALPS Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

ALPS Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-95,276
Closed -$1.92M – 1004
2021
Q3 		$1.92M Buy
95,276
+86,586
+996% +$2.39M 0.02% 325
2021
Q2 		$324K Sell
8,690
-129,384
-94% -$3.97M ﹤0.01% 785
2021
Q1 		$3.53M Buy
138,074
+3,489
+3% +$89.1K 0.03% 194
2020
Q4 		$2.96M Buy
134,585
+39,628
+42% +$873K 0.03% 216
2020
Q3 		$1.71M Sell
94,957
-5,880
-6% -$122K 0.03% 255
2020
Q2 		$2.56M Sell
100,837
-23,574
-19% -$508K 0.03% 210
2020
Q1 		$2.29M Sell
124,411
-13,508
-10% -$263K 0.04% 204
2019
Q4 		$3.04M Buy
137,919
+1,615
+1% +$32.5K 0.02% 192
2019
Q3 		$1.96M Sell
136,304
-6,696
-5% -$95.7K 0.02% 212
2019
Q2 		$2.25M Buy
+143,000
New +$1.94M 0.02% 214

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

ALPS Advisors's DRNA Position: Q4 2021 in Review

ALPS Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 95,276 shares — an estimated $1.92M sold.

ALPS Advisors first reported a position in DRNA in Q2 2019 and held it in 10 quarters. The position peaked at $3.53M in Q1 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • ALPS Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 95,276 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.92M.
  • ALPS Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2019 and held it in 10 quarters.
  • ALPS Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $3.53M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.